NuuVim Review
Best for: Low-cost compounded GLP-1s (injection or oral), flat all-dose pricing
DTC telehealth weight-loss program (NuuVim LLC, Texas) offering compounded semaglutide and compounded tirzepatide in BOTH injectable and oral forms, plus limited brand-name Ozempic and Zepbound. Flat all-dose pricing with no extra fees: compounded semaglutide (injectable or oral) starts at $79/mo for new GLP-1 users ($133/mo for current users); compounded tirzepatide (injectable or oral) starts at $133/mo for new users ($199/mo current users). Brand Ozempic starts at $1,498/mo and Zepbound at $1,892/mo. Online evaluation reviewed by partnered physicians and licensed nurse practitioners; medication shipped from named partner pharmacies. LegitScript Certified (ID 44673205) and HIPAA-compliant. Terms disclose service in all 50 states plus Washington D.C. and name two compounding pharmacy partners (Hallandale Pharmacy, Fort Lauderdale FL; Pharmacy Hub, Miami FL) - both already-known WLR-directory partners. CAUTION: no founder/medical-director named; pharmacy partner per-drug routing not specified; refund/cancellation policy not surfaced; copyright 2025 indicates a young operation.
Medium confidence · Last verified 2026-06-02 · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
NuuVim is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
NuuVim prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| All doses (new GLP-1 user) | compounded | $79 |
| All doses (new GLP-1 user) | compounded-oral | $79 |
| All doses (new GLP-1 user) | compounded | $133 |
| All doses (new GLP-1 user) | compounded-oral | $133 |
| Brand Ozempic (starting) | brand | $1498 |
| Brand Zepbound (starting) | brand | $1892 |
✓ Pros
- •Low compounded entry pricing - semaglutide from $79/mo, tirzepatide from $133/mo, with flat all-dose / no-extra-fee structure
- •Both injectable AND oral compounded options for semaglutide and tirzepatide (oral GLP-1 access is uncommon in the compounded category)
- •LegitScript Certified (ID 44673205, seal live) and HIPAA-compliant
- •Two compounding pharmacy partners named verbatim in Terms - Hallandale Pharmacy (Fort Lauderdale FL) and Pharmacy Hub (Miami FL) - BOTH already vetted WLR-directory partners (supply-chain corroboration)
- •Operating legal entity disclosed: NuuVim LLC, Texas governing law, AAA arbitration in Collin County TX
- •Service disclosed in all 50 states plus Washington D.C. per Terms
✗ Cons
- •NO founder, CEO, medical director, or pharmacist-in-charge named on the site or Terms
- •Refund and cancellation policy not surfaced on FAQ or homepage
- •Compounded medications are not FDA-approved
- •Which pharmacy fills which drug/form is not disclosed
- •Copyright year 2025 indicates a very young operation with no multi-year track record
- •Brand Ozempic/Zepbound prices ($1,498-$1,892/mo) are well above manufacturer self-pay channels
- •Terms note 'Some Services may not be available in all 50 states' without specifying which - exact per-service state list not published
Ready to start with NuuVim?
Starting at $79/month. See current pricing and start your free consultation.
Sources & methodology
Our NuuVim review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of June 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to NuuVim
Editorial score · methodology
Bodybuilding Health+
Best for: fitness-brand compounded GLP-1 with hormone and performance programs
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with NuuVim?
Starting at $79/month. See current pricing and start your free consultation.